Efficacy of Lisdexamfetamine in Adults With Moderate to Severe Binge-Eating Disorder: A Randomized Clinical Trial.

Autor:	Hudson JI; McLean Hospital/Harvard Medical School, Belmont, Massachusetts., McElroy SL; Lindner Center of HOPE, Mason, Ohio.; University of Cincinnati College of Medicine, Cincinnati, Ohio., Ferreira-Cornwell MC; At the time of the study, Shire Development LLC, Lexington, Massachusetts.; Now with GlaxoSmithKline, Collegeville, Pennsylvania., Radewonuk J; At the time of the study, Shire Development LLC, Lexington, Massachusetts.; Now with The Griesser Group, Conshohocken, Pennsylvania., Gasior M; At the time of the study, Shire Development LLC, Lexington, Massachusetts.; Now with BTG International, Philadelphia, Pennsylvania.
Jazyk:	angličtina
Zdroj:	JAMA psychiatry [JAMA Psychiatry] 2017 Sep 01; Vol. 74 (9), pp. 903-910.
DOI:	10.1001/jamapsychiatry.2017.1889
Abstrakt:	Importance: The ability of pharmacotherapies to prevent relapse and maintain efficacy with long-term treatment in psychiatric conditions is important. Objective: To assess lisdexamfetamine dimesylate maintenance of efficacy in adults with moderate to severe binge-eating disorder. Design, Setting, and Participants: A multinational, phase 3, double-blind, placebo-controlled, randomized withdrawal study including 418 participants was conducted at 49 clinical research study sites from January 27, 2014, to April 8, 2015. Eligible adults met DSM-IV-R binge-eating disorder criteria and had moderate to severe binge eating disorder (≥3 binge-eating days per week for 14 days before open-label baseline; Clinical Global Impressions-Severity [CGI-S] scores ≥4 [moderate severity] at screening and open-label baseline). Following a 12-week, open-label phase (dose optimization, 4 weeks [lisdexamfetamine dimesylate, 50 or 70 mg]; dose maintenance, 8 weeks), lisdexamfetamine responders (≤1 binge eating day per week for 4 consecutive weeks and CGI-S scores ≤2 at week 12) were randomized to placebo or continued lisdexamfetamine during a 26-week, double-blind, randomized withdrawal phase. Interventions: Lisdexamfetamine administration. Main Outcomes and Measures: The primary outcome variable, time to relapse (≥2 binge-eating days per week for 2 consecutive weeks and ≥2-point CGI-S score increases from randomized withdrawal baseline), was analyzed using a log-rank test (primary analysis); the analysis was stratified for dichotomized 4-week cessation status. Safety assessments included treatment-emergent adverse events. Results: Of the 418 participants enrolled in the open-label phase of the study, 411 (358 [87.1%] women; mean [SD] age, 38.3 [10.4] years) were included in the safety analysis set. Of 275 randomized lisdexamfetamine responders (placebo, n = 138; lisdexamfetamine, n = 137), the observed proportions of participants meeting relapse criteria were 3.7% (5 of 136) for lisdexamfetamine and 32.1% (42 of 131) for placebo. Lisdexamfetamine demonstrated superiority over placebo on the log-rank test (χ21, 40.37; P < .001) for time to relapse; the hazard ratio, based on a Cox proportional hazards model for lisdexamfetamine vs placebo, was 0.09 (95% CI, 0.04-0.23). The treatment-emergent adverse events observed were generally consistent with the known profile of lisdexamfetamine. Conclusions and Relevance: Risk of binge-eating relapse over 6 months was lower in participants continuing lisdexamfetamine than in those randomized to placebo. The hazard for relapse was lower with lisdexamfetamine than placebo. Trial Registration: clinicaltrials.gov Identifier: NCT02009163.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu